Company intelligence / Profile preview

Alibaster

Ownership: Private
Development stage: Other

Overview

Alabaster appears to be an active private investment firm rather than a life science, biotech, pharma, or healthcare operating company. Publicly available descriptions indicate that it invests in founders building breakthrough, science-based companies intended to create positive planet-level impact. The firm presents itself as backing differentiated technology companies rather than developing therapeutic products, diagnostics, or healthcare services directly. Based on the available evidence, it does not appear to have a drug pipeline, clinical-stage assets, or healthcare-focused operating programs.

Industry: Investors

Beyond the preview

Go deeper on Alibaster.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alibaster.

Explore the full profile